| Maura Frances O'neil, MD | |
|
4000 Cambridge St, Kansas City, KS 66160-0001 | |
| (913) 588-7073 | |
| (913) 588-7073 |
| Full Name | Maura Frances O'neil |
|---|---|
| Gender | Female |
| Speciality | Pathology |
| Experience | 20 Years |
| Location | 4000 Cambridge St, Kansas City, Kansas |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083746283 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207ZP0102X | Pathology - Anatomic Pathology & Clinical Pathology | 94-06218 (Kansas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Of Kansas Hospital | Kansas city, KS | Hospital |
| Olathe Medical Center | Olathe, KS | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Kansas University Physicians, Inc. | 8921911587 | 1456 |
| University Of Kansas Hospital Authority | 9436054798 | 250 |
News Archive
Scientists have discovered that a biological molecule important in cell growth (STAT3) is also critical in protecting us against infection - so much so that we would be unable to fight the common flu virus without it.
As they develop, vertebrate embryos form vertebrae in a sequential, time-controlled way. Scientists have determined previously that this process of body segmentation is controlled by a kind of "clock," regulated by the oscillating activity of certain genes within embryonic cells. But questions remain about how precisely this timing system works.
Tolero Pharmaceuticals, Inc., a late clinical-stage biopharmaceutical company developing treatments for oncology and blood disorders, reported positive interim results from an ongoing, randomized Phase 2 clinical trial of its lead drug candidate, alvocidib, in combination with cytarabine plus mitoxantrone for previously untreated acute myeloid leukemia (AML) patients.
The ONCOMMUN Program will receive a grant worth 900,000 euros for 2019-2020 by the European Institute of Innovation & Technology which will be used to promote well-being in cancer through new technologies.
› Verified 6 days ago
| Entity Name | Kansas University Physicians, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003858333 PECOS PAC ID: 8921911587 Enrollment ID: O20040401000328 |
News Archive
Scientists have discovered that a biological molecule important in cell growth (STAT3) is also critical in protecting us against infection - so much so that we would be unable to fight the common flu virus without it.
As they develop, vertebrate embryos form vertebrae in a sequential, time-controlled way. Scientists have determined previously that this process of body segmentation is controlled by a kind of "clock," regulated by the oscillating activity of certain genes within embryonic cells. But questions remain about how precisely this timing system works.
Tolero Pharmaceuticals, Inc., a late clinical-stage biopharmaceutical company developing treatments for oncology and blood disorders, reported positive interim results from an ongoing, randomized Phase 2 clinical trial of its lead drug candidate, alvocidib, in combination with cytarabine plus mitoxantrone for previously untreated acute myeloid leukemia (AML) patients.
The ONCOMMUN Program will receive a grant worth 900,000 euros for 2019-2020 by the European Institute of Innovation & Technology which will be used to promote well-being in cancer through new technologies.
› Verified 6 days ago
| Entity Name | University Of Kansas Hospital Authority |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1528019502 PECOS PAC ID: 9436054798 Enrollment ID: O20050908001103 |
News Archive
Scientists have discovered that a biological molecule important in cell growth (STAT3) is also critical in protecting us against infection - so much so that we would be unable to fight the common flu virus without it.
As they develop, vertebrate embryos form vertebrae in a sequential, time-controlled way. Scientists have determined previously that this process of body segmentation is controlled by a kind of "clock," regulated by the oscillating activity of certain genes within embryonic cells. But questions remain about how precisely this timing system works.
Tolero Pharmaceuticals, Inc., a late clinical-stage biopharmaceutical company developing treatments for oncology and blood disorders, reported positive interim results from an ongoing, randomized Phase 2 clinical trial of its lead drug candidate, alvocidib, in combination with cytarabine plus mitoxantrone for previously untreated acute myeloid leukemia (AML) patients.
The ONCOMMUN Program will receive a grant worth 900,000 euros for 2019-2020 by the European Institute of Innovation & Technology which will be used to promote well-being in cancer through new technologies.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Maura Frances O'neil, MD 3901 Rainbow Blvd, Kansas City, KS 66103-2937 Ph: (913) 588-7103 | Maura Frances O'neil, MD 4000 Cambridge St, Kansas City, KS 66160-0001 Ph: (913) 588-7073 |
News Archive
Scientists have discovered that a biological molecule important in cell growth (STAT3) is also critical in protecting us against infection - so much so that we would be unable to fight the common flu virus without it.
As they develop, vertebrate embryos form vertebrae in a sequential, time-controlled way. Scientists have determined previously that this process of body segmentation is controlled by a kind of "clock," regulated by the oscillating activity of certain genes within embryonic cells. But questions remain about how precisely this timing system works.
Tolero Pharmaceuticals, Inc., a late clinical-stage biopharmaceutical company developing treatments for oncology and blood disorders, reported positive interim results from an ongoing, randomized Phase 2 clinical trial of its lead drug candidate, alvocidib, in combination with cytarabine plus mitoxantrone for previously untreated acute myeloid leukemia (AML) patients.
The ONCOMMUN Program will receive a grant worth 900,000 euros for 2019-2020 by the European Institute of Innovation & Technology which will be used to promote well-being in cancer through new technologies.
› Verified 6 days ago
Dr. Mark T Cunningham, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 3901 Rainbow Blvd, Dept Of Pathology, Kansas City, KS 66160 Phone: 913-588-7070 Fax: 913-588-7073 | |
Anders Meyer, Pathology Medicare: Accepting Medicare Assignments Practice Location: 4000 Cambridge St, Kansas City, KS 66160 Phone: 913-588-7090 | |
Christopher Jurief, DO Pathology Medicare: Medicare Enrolled Practice Location: 3901 Rainbow Blvd, Kansas City, KS 66160 Phone: 913-945-7972 | |
Dr. Diane L Persons, MD Pathology Medicare: Not Enrolled in Medicare Practice Location: 3901 Rainbow Blvd, Dept Of Pathology, Kansas City, KS 66160 Phone: 913-588-7070 Fax: 913-588-7073 | |
Dr. Zhan Ye, M.D., PH.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 4000 Cambridge St, Kansas City, KS 66160 Phone: 913-588-1651 | |
Dr. Kathy L Newell, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 3901 Rainbow Blvd, Dept Of Pathology, Kansas City, KS 66160 Phone: 913-588-7070 Fax: 913-588-7073 |